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Traditional Chinese medicine (TCM) treatment is based on the traditional diagnose method to distinguish the TCM syndrome,
not the disease. So there is a phenomenon in the relationship between TCM syndrome and disease, called Same TCM Syndrome
for Diﬀerent Diseases and Diﬀerent TCM Syndrome for Same Disease. In this study, we demonstrated the molecular mechanisms
of this phenomenon using the microarray samples of liver-gallbladder dampness-heat syndrome (LGDHS) and liver depression
and spleen deﬁciency syndrome (LDSDS) in the chronic hepatitis B (CHB) and liver cirrhosis (LC). The results showed that the
diﬀerencebetweenCHBandLCwasgeneexpressionlevelandthediﬀerencebetweenLGDHSandLDSDSwasgenecoexpressionin
theG-protein-coupledreceptorprotein-signalingpathway.ThereingenesGPER,PTHR1,GPR173,andSSTR1werecoexpressedin
LDSDS, but not in LGDHS. Either CHB or LC was divided into the alternative LGDHS and LDSDS by the gene correlation, which
reveals the molecular feature of Diﬀerent TCM Syndrome for Same Disease. The alternatives LGDHS and LDSDS were divided
into either CHB or LC by the gene expression level, which reveals the molecular feature of Same TCM Syndrome for Diﬀerent
Diseases.
1.Introduction
Traditional Chinese medicine (TCM) is a medical system
with at least 3000 years of uninterrupted clinical practice in
China. The TCM practice usually requires a TCM syndrome
identiﬁcation basedon clinical manifestation followedby the
use of individualized treatment that is adapted to address the
particular TCM syndrome in patient [1]. Therefore, TCM
syndrome, also called ZHENG or TCM pattern, is the core
of diagnosis and treatment in TCM [2]. Nowadays, TCM
syndrome had been studied in some speciﬁc disease such
as hypertension [3], coronary heart disease [4], and rheu-
matoid arthritis [5] or biomedical condition such as neuro-
endocrine-immune network [6], suggesting that TCM syn-
dromes are signiﬁcantly associated with diseases.
Hepatitis B is a viral infection that attacks the liver and
can cause both acute and chronic disease. Beyond 25% of
hepatitis B virus-infected patients would die of severe
chronic liver diseases such as liver cirrhosis and liver cancer
[7]. Chronic hepatitis B (CHB) and liver cirrhosis (LC) are
the intractable diseases that remain a major public health
problem worldwide. Although several antiviral drugs had
been approved for CHB, they caused signiﬁcant side eﬀects
and drug resistance. In contrast, TCM treatment was regard-
ed as a safe and eﬀective method for CHB and Liver ﬁbrosis
[8, 9].
TCM treatment is based on the traditional diagnose
method to diﬀerentiate the TCM syndrome, not the disease
in western medicine. Therefore, TCM syndromes could be
classiﬁed in CHB as well as in LC. Moreover, diﬀerent
patients, respectively, suﬀering CHB or LC could also belong
to the same TCM syndrome. This phenomenon is called
Same TCM Syndrome for Diﬀerent Diseases and Diﬀerent
TCM syndrome for Same Disease [10–12]. This viewpoint in
TCM is very diﬀerent with Western medicine. The molecular
mechanism of this phenomenon is still a mystery.2 Evidence-Based Complementary and Alternative Medicine
Previous study reported liver-gallbladder dampness-
heat syndrome (LGDHS) and liver depression and spleen
deﬁciency syndrome (LDSDS) are the major syndromes in
CHB [13, 14]. In this study, the aim is to demonstrate the
molecular mechanism of Same TCM Syndrome for Diﬀerent
Diseases and Diﬀerent TCM Syndrome for Same Disease by
the analysis of whole gene expression in the same syndrome
as LGDHS or LDSDS of diﬀe r e n td i s e a s e sa sC H Ba n dL C
and the same disease as CHB or LC of diﬀerent syndromes as
LGDHS and LDSDS.
2.MaterialandMethods
2.1. Samples. Blood samples from 92 patients were obtained.
Therein 14 samples from 2 LGDHS and 3 LDSDS in CHB
patients,3LGDHSand3LDSDSinLCpatientsand3healthy
peoples were used to microarray test, and 78 samples from
20 LGDHS and 18 LDSDS in CHB patients, and 21 LGDHS
and 19 LDSDS in LC patients were used to test and verify
the accuracy of the result. All patients were from Shanghai
Longhua Hospital and have signed an agreement with us.
The blood samples were morning fasting venous blood and
saved in −20◦C with 150µL EDTA.
2.2. RNA Extraction and Microarrays. Total RNA of leuko-
cyte from the whole blood was extracted using TRIzol Rea-
gent (Invitrogen, Carlsbad, CA, USA), and a quality control
was carried out with NanoDrop ND-1000. The cDNAs were
synthesized by the Invitrogen First-Strand cDNA Synthesis
kits (Invitrogen, Carlsbad, CA, USA), and RNA polymerase
was added to degrade RNA. The cDNA was labeled and
hybridized using NimbleGen Homo sapiens 12x135K Arrays
(Roche NimbleGen, Madison, WI, USA), according to the
manufacturer’s protocol.
2.3. Real-Time RT-PCR. Diﬀerence-expressed mRNAs were
veriﬁed by real-time RT-PCR according to SYBR Green
Realtime PCR Master Mix kit (TOYOBO, Osaka, Japan)
manufacturer. The primer sequences were F: TGGTGT-
GCGCAGCCATCGTG, R: GCCAGTAACCGGCCACCTCG
for DRD5; F: GCTCTGTCAGGGCTCAACCTCC, R: GGC-
ACAAACTTGGAGAGACCGAGC for GABRA; F: GCT-
ACGTGGCCGTGGTGCAT, R: CCGCGGTGCGAGAGA-
AGACC for SSTR1; F: AGCGAACCCCTCCCACCACA, R:
CAGGAAGGCTTGGCTCCGGC for NPFF. F: ACAGAG-
CCTCGCCTTTGCCG, R: ACATGCCGGAGCCGTTGTCG
for ACTB.
2.4.MicroarrayDataPreprocessingandStatisticAnalysis. Mi-
croarray data preprocessing was performed using the Gene-
Pix software. Raw expression data were log2 transformed
and normalized by quantile normalization. Probes were
considered robustly expressed if Signal/Noise (SNR) < 2.
We took the average of 3 healthy people in every probe
and let every patient sample ratio be this average in every
probe.Inallthefollowingpages:CHBmeanschronichepati-
tis B versus normal; LC means liver cirrhosis versus normal;
LGDHS means liver-gallbladder dampness-heat syndrome
versus normal; LDSDS means spleen deﬁciency syndrome
versus normal.
The t-test function in R software was used to select
diﬀerence expressed gene (threshold: P value < 0.01 or P
value < 0.05) in diseases between CHB and LC as well
as in TCM syndromes between LGDHS and LDSDS. GO
enrichment analysis was executed using the selected genes.
Heatmap analysis, also executed in R, was computing the
hierarchical clustering in both rows and columns according
tothesetofgenevaluesanddrawingacolorimageasavisible
result.
The correlation analysis was used to analyze the corre-
lation of diﬀerence expressed genes between CHB and LC
or LGDHS and LDSDS. The level of signiﬁcance was set at
correlation coeﬃcient >0.5.
2.5. Gene Module Analysis and Diﬀerence Coexpression Analy-
sis. The Weighted Correlation Network Analysis (WGCNA)
R package was used to run the gene module analysis (pa-
rameter: networkType = signed, detectCutHeight = 0.97).
WGCNA was a systems biology method to describe the cor-
relation patterns among genes across microarray samples. It
wasusedtoﬁndclusters(modules)ofhighlycorrelatedgenes
and summarizing the clusters using the Module Eigengene
(ME) [15].
Furthermore, coXpress R package was used to analyze
the diﬀerence coexpression (parameter: s = pearson, m =
average, h = 0.4). coXpress as a tool has been applied to
identifygroupsofgenesthatdisplaydiﬀerentialcoexpression
patterns in microarray datasets and its utility [16].
3. Results and Discussion
3.1. Diﬀerence Expression Analysis. At ﬁrst, to ﬁnd whether
there were some signiﬁcant genes that could characterize the
diﬀerence between two disease and two TCM syndromes,
t-test was used to select diﬀerence expression gene in both
disease and TCM syndrome levels. The threshold was P
value less than 0.01. Remarkably, 6579 in all 14352 genes
werediﬀerentiallyexpressedbetweenCHBandLC,suggested
that the diﬀerence in mRNA expression level was very clear,
according to CHB and LC that were completely diﬀerent
diseases. In contrast, only 98 genes were diﬀerentially
expressed between LGDHS and LDSDS. The heatmap of
the 98 genes between LGDHS and LDSDS was showed
in Figure 1. Moreover, though these genes were obviously
diﬀerentiated into two syndromes, the 98 genes were in
disorder, no signiﬁcantly related function was found by GO
enrichment analysis. It also was tried to change the threshold
as P value less than 0.05 and got 830 genes, but still any
signiﬁcantly related GO function was not found.
3.2. Gene Modules Related with Disease or TCM Syndrome.
Due to the above result that the molecular mechanisms
of the diﬀerence between two TCM syndromes could be
not commendably explained with the single-gene diﬀerence
expression method, then the gene module method was used
to demonstrate the diﬀerence between diseases and TCMEvidence-Based Complementary and Alternative Medicine 3
B
5
B
4
E
5
E
6
E
4
A
1
A
3
A
2
D
1
D
3
D
2 11270 11243 10094 83463 58 10238 6839 5439 125950 84559 6382 1158 125893 284338 3090 25807 10272 727800 92002 56905 283989 414 9274 1859 548593 7378 10181 51699 80060 728492 10380 56990 55027 84124 129685 83637 4122 7188 10097 23567 146923 56160 11276 3218 4495 859 2064 388585 285150 503497 2263 54466 7768 441381 340385 79935 84142 147686 541468 337 6528 401166 139599 9048 10282 3882 2520 81789 1446 55539 389434 10590 79933 8352 3764 27295 64854 91442 83697 148523 388199 130026 80264 147948 27296 148423 5165 29044 54797 132320 51362 23252 125875 90673 161882 142891 55275 100129408
LGDHS LDSDS
Figure 1: Heatmap of 98 diﬀerentially expressed genes between LGDHS and LDSDS. The 98 diﬀerentially expressed genes between LGDHS
and LDSDS were obviously divided out by Heatmap analysis. Row: genes; column: patient number; deep colour: upexpressed genes; light
colour: down-expressed genes; A1–3 and D1–3: LDSDS; B 4, 5 and E4–6: LGDHS.
syndromes. The all 14352 genes were taken into 26 gene
modules by the WGCNA R package [15], and each module
hadanameofcolorandaMEtoidentifythegeneexpression.
Among the 26 modules, some signiﬁcant modules were
screened out by correlating the MEs in our disease trail or
TCM syndrome trail. In the result, blue, brown, turquoise,
and yellow modules were most related with the diﬀerence
between CHB and LC (Figure 2(a)), and lightgreen module
and lightcyan module were most related with the diﬀerence
between LGDHS and LDSDS (Figure 2(b)).
The above 6 gene modules were used to GO enrichment
analysis. The result showed that the blue module was mainly
enriched in G-protein-coupled receptor protein-signaling
pathway, brown module was mainly enriched in immune
system process, yellow module was mainly enriched in
cell cycle, and turquoise module was enriched in many
basal metabolisms. But it was still hard to understand that
ossiﬁcation function was enriched in lightcyan module, and
the lightgreen module did not enrich in any GO function
module.
3.3. Comparing Diﬀerence Coexpression Network between Two
TCM Syndromes. To further demonstrate the mechanism of
diﬀerence between two TCM syndromes, the correlation of
gene expression including diﬀerence expression and diﬀer-
ence coexpression was analyzed. Figure 3 was a schematic
diagram which showed the meaning of diﬀerence expres-
sion or diﬀerence coexpression, respectively. The diﬀerence
expression meant that there were gene diﬀerent expression
levels between two states. The diﬀerence coexpression meant4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Average gene expression in modules which correlated with diseases or TCM syndromes. In the diseases (a), blue and brown
modules both had low expression value in CHB and not consistent in LC. Yellow and turquoise modules both had high expression value in
CHB and not consistent in LC. In the TCM syndromes (b), lightcyan modules had low expression value in LDSDS. Lightgreen modules had
high expression value in LDSDS. A1–3 and D1–3: LDSDS; B 4, 5 and E4–6: LGDHS.
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Figure 3: Schematic diagram of diﬀerence expression and diﬀerence coexpression. Graph of the diﬀerence expression (a) represented that
there are genes diﬀerent expression levels between states A and B, and the diﬀerence coexpression (b) represented that there is higher
correlation in state A and lower correlation in state B. Curves were represented as whichever genes.
that there was higher gene correlation in a state and lower
gene correlation in another state.
Then, the diﬀerence coexpression groups between
LGDHS and LDSDS were analyzed using the advantage of
coXpress R package [16]. First, through the analysis using
the 830 diﬀerential expression genes (P<0.05 in t-test)
between the LGDHS and LDSDS, the gene groups whose
gene members were coexpressed in LGDHS and not co-
expressed in LDSDS were produced by coXpress (A in
Table 1). Then we also executed the coXpress again to ﬁnd
the gene groups whose gene members were coexpressed in
LDSDS and not coexpressed in LGDHS (B in Table 1). The P
values including p.g1 in and p.g2 indicated a gene confusion
degree in every group in LGDHS or LDSDS, respectively,
(P>0.05 was jumbled or not coexpressed; P<0.05 was
order or coexpressed).
It was found that the gene coexpression groups were
orderly in LGDHS but jumbled in LDSDS (A in Table 1).
Among the groups jumbled in LDSDS, There were the most
g e n en u m b e r si ng r o u p9 .T h eg e n ec o n f u s i o nd e g r e ei n
group9wasshowedinFigure 4.Itwasobservedthatgenesof
LGDHS in group 9 had similar traces (Figure 4(a)), whereasEvidence-Based Complementary and Alternative Medicine 5
Table 1: Comparison of gene coexpression groups in LGDHS and
LDSDS.
Group ID Gene number P.g1 P.g2
AL G D H S
8 6 0.00 0.62
5 10 0.00 0.31
9 81 0.00 0.83
14 18 0.00 0.38
12 34 0.00 0.11
17 15 0.00 0.05
13 45 0.00 0.14
10 58 0.00 0.03
4 19 0.00 0.15
16 27 0.00 0.02
15 55 0.00 0.00
3 48 0.00 0.00
6 16 0.00 0.01
11 92 0.00 0.00
2 11 0.00 0.00
1 234 0.00 0.00
7 61 0.00 0.00
B LDSDS
9 6 0.00 0.00
17 10 0.00 0.00
12 13 0.01 0.00
7 297 0.00 0.00
14 5 0.12 0.00
4 90 0.00 0.00
8 5 0.20 0.00
10 12 0.04 0.00
5 69 0.53 0.00
6 26 0.83 0.00
15 3 0.49 0.08
2 238 0.69 0.00
3 21 0.87 0.00
11 8 0.54 0.00
1 8 0.36 0.00
13 4 0.62 0.05
18 6 0.83 0.00
16 9 0.76 0.07
the traces of LDSDS were varied (Figure 4(b)). To further
clarify the functional mechanism at molecular level, GO
enrichment analysis was taken on the genes in group 9. As
Table 2 revealed, LGDHS was involved in electron transport
chain function, but LDSDS does not.
Analogously, it was also found that the gene coexpression
groups were orderly in LDSDS but jumbled in LGDHS (B
in Table 1). Among the groups jumbled in LGDHS, there
were the most gene numbers in group 2. Therefore, group
2 were analyzed and showed that the traces of LGDHS
were varied (Figure 4(c)) and the traces of LDSDS were in
order (Figure 4(d)). Through further studied the molecular
functional mechanism by the GO enrichment analysis, it
was found that LDSDS was involved in G-protein-coupled
receptor protein-signaling pathway (GCRP pathway), but
LGDHS does not (Table 2).
3.4. Molecular Mechanism of Diﬀerence between Diseases
and TCM Syndromes. It was interesting in our result that
the genes coexpression in group 2 was enriched in GCRP
pathway. Because same situation happened to the genes in
blue module, which was related with the diﬀerence between
CHB and LC by the gene module analysis, these genes
in GCRP pathway were diﬀerentially expressed between
CHB and LC and diﬀerence coexpressed between LGDHS
and LDSDS. These results were summarized in Figure 5.
Interestingly, in GCRP pathway, whether TCM syndrome
was LGDHS or LDSDS, the gene expression level was lower
in CHB and higher or lower in LC, and whether disease
was CHB or LC, the genes in LDSDS had higher correlation
than LGDHS. For example, in LDSDS, genes GPER, PTHR1,
GPR173,andSSTR1wereconnectedinacorrelationnetwork
together, while they, respectively, belong to four correlation
networks in LGDHS (Figure 5). These results suggested the
diﬀerent molecular mechanism between diseases (CHB and
LC) and TCM syndromes (LGDHS and LDSDS).
3.5. Average Expression and Correlation of DRD5 GABRA
SSTR1 and NPFF Genes in Diseases and TCM Syndromes. To
test and verify the diﬀerence of average expression level and
correlationofgenesinGCRPpathway,DRD5GABRASSTR1
and NPFF mRNAs were expressed by real-time RT-PCR. The
average expression levels of these genes in both LGDHS and
LDSDS were lower in CHB, and that of LDSDS was more
than LGDHS in LC (Figure 6(a)). The correlation coeﬃcient
of LDSDS (>0.5) in CHB and LC was more than LGDHS
(<0.5) in CHB and LC (Figure 6(b)). These results further
conﬁrmed that the gene expression level was lower in CHB
and higher or lower in LC. The genes in LDSDS had higher
correlation than LGDHS whether disease was CHB or LC.
Previous researches had also found that LC was related
with GCRP pathway [17–19], but little literature touched
upon the relation between CHB and GCRP. Our result
also indicated that genes in GCRP pathway were higher
expression in LC and lower expression in CHB. It suggested
that LC was a more serious disease than CHB by the activity
of GCRP pathway. Further research will clarify the role of
genes in GCRP pathway from CHB develop to LC.
Interestingly, our results showed that TCM syndromes,
LGDHS and LDSDS did not clearly relate with the gene
expression levels in GCRP pathway. The genes correlation
or cooperation was more important. As shown in Figure 4,
the genes in LDSDS had more connections than LGDHS, so
LGDHS and LDSDS constructed diﬀerent gene network. It
incarnated the holistic thought in TCM.
Therefore, our research results suggested that CHB could
be divided into LGDHS and LDSDS by the gene correlation
aswellasLC,whichrevealsthemolecularfeatureofDiﬀerent
TCM Syndrome for Same Disease. Analogously, LGDHS was
being in CHB or LC by the gene expression level as well as
LDSDS, which reveals the molecular feature of Same TCM6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: The gene confusion degree of group 2 and 9 in LGDHS and LDSDS. CoXpress was used to ﬁnd orderly gene groups in LGDHS
or LDSDS. The genes in group 9 of orderly gene groups in LGDHS showed good consistency in LGDHS (a) and poor consistency in LDSDS
(b). The genes in group 2 of orderly gene groups in LDSDS showed poor consistency in LGDHS (c) and good consistency in LDSDS (d).
A1–3 and D1–3: LDSDS; B 4, 5 and E4–6: LGDHS.
Syndrome for Diﬀerent Diseases. The schematic diagram of
the molecular mechanisms was showed in Figure 2.
There are two kinds of therapeutic principles in the
TCM syndrome identiﬁcation and treatment process, called
Diﬀerenttreatmentsforthesamediseaseandsametreatment
for diﬀerent diseases. The Diﬀerent treatments for the same
diseasemeansusingdiﬀerentprescriptionsorChineseherbal
medicines to treat the diﬀerent TCM syndromes in the same
disease process. The Same treatment for diﬀerent diseases
means using the same and prescriptions or Chinese herbal
medicines to treat the same TCM syndrome in different
disease process. These therapeutic principles are widely used
in TCM practice as personalized therapy [12, 20]. Therefore,
understanding the molecular mechanisms of Same TCM
Syndrome for Diﬀerent Diseases and Diﬀerent TCM Syn-
drome for Same Disease will be primely serving for TCMEvidence-Based Complementary and Alternative Medicine 7
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Figure 6: Average expression and correlation of DRD5 GABRA SSTR1 and NPFF mRNAs in diseases and TCM syndromes. The gene
expression levels of both LGDHS and LDSDS were lower in CHB and that of LDSDS was more than LGDHS in LC (a). (Gene expression
levels were the ratio of each mRNA and ACTB mRNA). The correlation coeﬃcient of LDSDS in CHB and LC was more than LGDHS in
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Table 2: GO enrichments of orderly group 2 in LDSDS and group 9 in LGDHS.
GO term ID Orderly group Enrichment P Term name
GO:0006120 LGDHS 9 0.022478 Mitochondrial electron transport, NADH to ubiquinone
GO:0022900 LGDHS 9 0.022478 Electron transport chain
GO:0022904 LGDHS 9 0.022478 Respiratory electron transport Chain
GO:0042773 LGDHS 9 0.022478 ATP synthesis coupled electron transport
GO:0042775 LGDHS 9 0.022478 Organelle ATP synthesis coupled electron transport
GO:0006119 LGDHS 9 0.04236 Oxidative phosphorylation
GO:0010468 LGDHS 9 0.048855 Regulation of gene expression
GO:0009987 LGDHS 9 0.049535 Cellular process
GO:0016070 LGDHS 9 0.059695 RNA metabolic process
GO:0006355 LGDHS 9 0.061016 Regulation of transcription, DNA-dependent
GO:0007186 LDSDS2 0.000668 G-protein coupled receptor protein signaling pathway
GO:0007606 LDSDS2 0.004518 Sensory perception of chemical stimulus
GO:0007608 LDSDS2 0.004518 Sensory perception of smell
GO:0007166 LDSDS2 0.014079 Cell surface receptor linked signal transduction
GO:0007586 LDSDS2 0.015106 digestion
GO:0007223 LDSDS2 0.017534 Wnt receptor signaling pathway, calcium modulating pathway
GO:0008203 LDSDS2 0.017534 Cholesterol metabolic process
GO:0016125 LDSDS2 0.017534 Sterol metabolic process
GO:0042157 LDSDS2 0.017534 Lipoprotein metabolic process
GO:0006813 LDSDS2 0.017952 Potassium ion transport
diagnosis and treatment. This research provided ﬁrstly the
evidence. Further research will be required more samples to
proving this evidence.
4. Conclusion
The classiﬁcation of TCM syndrome is a diagnostic method.
TCM syndromes are signiﬁcantly associated with diseases,
which are involved in Same TCM Syndrome for Diﬀerent
Diseases and Diﬀerent TCM Syndrome for Same Disease.
In this study, through analyzing microarray date of LGDHS
and LDSDS in patients with CHB and LC, we provided
evidence that the diﬀerence between CHB and LC was
gene expression and the diﬀerence between LGDHS and
LDSDS was gene coexpression in G-protein-coupled recep-
tor protein-signaling pathway. Therein genes GPER, PTHR1,
GPR173, and SSTR1 were coexpressed in LDSDS but not in
LGDHS. Either CHB or LC was divided into the alternative
LGDHS and LDSDS by the gene correlation, which reveals
the molecular feature of Diﬀerent TCM Syndrome for Same
Disease. Either LGDHS or LDSDS was divided into the
alternative CHB and LC by the gene expression level, which
reveals the molecular feature of Same TCM Syndrome for
DiﬀerentDiseases.Theseresultsmightbesigniﬁcantforboth
TCM research and TCM diagnosis and treatment.
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